HealthDay on MSN23h
Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus Surgery
A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to a study published ...
pharmaphorum18h
FDA starts review of first bronchiectasis drug candidate
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
Zacks.com on MSN16h
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
Pharmabiz23h
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...